Leuthold Group Decreased Meritage Homes Corp. (MTH) Holding; Progenics Pharmaceuticals (PGNX) Sentiment Is 1.28

Meritage Homes Corporation (NYSE:MTH) Logo

Leuthold Group Llc decreased Meritage Homes Corp. (MTH) stake by 10.43% reported in 2018Q4 SEC filing. Leuthold Group Llc sold 8,460 shares as Meritage Homes Corp. (MTH)’s stock rose 14.67%. The Leuthold Group Llc holds 72,665 shares with $2.67M value, down from 81,125 last quarter. Meritage Homes Corp. now has $1.65 billion valuation. The stock decreased 0.53% or $0.23 during the last trading session, reaching $43.16. About 775,690 shares traded or 67.53% up from the average. Meritage Homes Corporation (NYSE:MTH) has risen 3.47% since March 15, 2018 and is uptrending. It has underperformed by 0.90% the S&P500. Some Historical MTH News: 13/03/2018 Meritage Homes Closes Above 200-Day Moving Average: Technicals; 09/05/2018 – Meritage Homes Presenting at JPMorgan Conference May 15; 22/03/2018 – BEIJING NEW BUILDING MATERIALS PUBLIC 000786.SZ SAYS IT SETTLES LITIGATION WITH U.S. HOME BUILDER MERITAGE HOMES OF FLORIDA INC OVER BEIJING NEW BUILDING MATERIALS’ PLASTERBOARDS; 02/04/2018 – Meritage Homes Earns Sixth Consecutive ENERGY STAR® Partner of the Year—Sustained Excellence Award for Leadership in Energy-Efficient Homebuilding; 28/03/2018 – Meritage Capital to Join Brown Advisory; 18/05/2018 – Meritage Announces Results of 2018 Annual Meeting; 25/04/2018 – MERITAGE HOMES 1Q EPS $1.07, EST. 73C; 26/04/2018 – Meritage Homes Closes Above 50-Day Moving Average: Technicals; 09/05/2018 – Meritage Homes Presentation at J.P. Morgan Homebuilding and Building Products Conference to be Webcast Live on May 15, 2018; 25/04/2018 – Meritage 1Q Net $43.9M

Progenics Pharmaceuticals Inc (PGNX) investors sentiment decreased to 1.28 in 2018 Q4. It’s down -0.13, from 1.41 in 2018Q3. The ratio has dropped, as 68 active investment managers opened new or increased holdings, while 53 cut down and sold their positions in Progenics Pharmaceuticals Inc. The active investment managers in our database now possess: 69.33 million shares, down from 73.30 million shares in 2018Q3. Also, the number of active investment managers holding Progenics Pharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 41 Increased: 42 New Position: 26.

It closed at $4.42 lastly. It is up 33.53% since March 15, 2018 and is downtrending. It has underperformed by 37.90% the S&P500. Some Historical PGNX News: 22/03/2018 – PROGENICS SAYS FDA EXTENDS NDA REVIEW FOR AZEDRA TO JULY 30; 22/03/2018 – Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane l 131); 14/03/2018 – Progenics Forms Golden Cross: Technicals; 22/03/2018 – Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131); 19/03/2018 – PROGENICS STUDY OF AZEDRA ACHIEVED PRIMARY, SECONDARY ENDPOINTS; 22/05/2018 – Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform; 11/05/2018 – PROGENICS PHARMA- CO,OTHER PLAINTIFFS ALLEGE PRODUCTS FOR WHICH PAR IS SEEKING U.S. MARKETING APPROVAL INFRINGES CO’S,OTHER PLAINTIFFS’ U.S. PATENTS; 22/03/2018 – PROGENICS PHARMACEUTICALS REPORTS THREE-MONTH EXTENSION OF PDUF; 22/05/2018 – Progenics Pharma: Data Support Prognostic Utility of aBSI as Imaging Biomarker for Survival With Castration-Resistant Prostate Cancer; 11/05/2018 – Progenics And Fellow Plaintiffs Valeant, Salix and Wyeth Reach Patent Settlement With Par Pharmaceutical

More notable recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Nasdaq.com which released: “Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent – Nasdaq” on March 14, 2019, also Nasdaq.com with their article: “Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14 – Nasdaq” published on March 07, 2019, Nasdaq.com published: “Pre-Market Earnings Report for March 14, 2019 : DG, GDS, ERJ, AZUL, LX, GCO, RDNT, KNOP, HUD, BIOS, PPDF, PGNX – Nasdaq” on March 13, 2019. More interesting news about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were released by: Seekingalpha.com and their article: “Progenics Pharma shares halted pending news – Seeking Alpha” published on September 12, 2018 as well as Seekingalpha.com‘s news article titled: “Progenics shares halted pending news – Seeking Alpha” with publication date: October 05, 2018.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $373.68 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Armistice Capital Llc holds 1.81% of its portfolio in Progenics Pharmaceuticals, Inc. for 5.70 million shares. Phocas Financial Corp. owns 1.70 million shares or 0.8% of their US portfolio. Moreover, Rice Hall James & Associates Llc has 0.29% invested in the company for 1.92 million shares. The New York-based Pinnacle Associates Ltd has invested 0.16% in the stock. Farallon Capital Management Llc, a California-based fund reported 4.20 million shares.

Analysts await Meritage Homes Corporation (NYSE:MTH) to report earnings on April, 24. They expect $0.64 earnings per share, down 40.19% or $0.43 from last year’s $1.07 per share. MTH’s profit will be $24.41 million for 16.86 P/E if the $0.64 EPS becomes a reality. After $1.91 actual earnings per share reported by Meritage Homes Corporation for the previous quarter, Wall Street now forecasts -66.49% negative EPS growth.

Investors sentiment increased to 1.3 in Q4 2018. Its up 0.36, from 0.94 in 2018Q3. It is positive, as 26 investors sold MTH shares while 40 reduced holdings. 27 funds opened positions while 59 raised stakes. 36.76 million shares or 2.21% less from 37.59 million shares in 2018Q3 were reported. Victory Capital Mgmt Inc, Ohio-based fund reported 10,079 shares. Captrust Financial Advsrs accumulated 1,096 shares. Mcf Advisors Lc reported 0% stake. Citigroup invested in 20,546 shares. 40,000 were reported by Country Club Na. State Of Wisconsin Board holds 130,000 shares or 0.02% of its portfolio. Engineers Gate Manager Limited Partnership reported 55,250 shares. Pictet Asset Mngmt owns 86,495 shares. Vanguard Grp has 3.85 million shares. Earnest Ltd Llc reported 2.06M shares. Commonwealth Financial Bank Of Australia reported 6,100 shares. New Amsterdam Partners Ltd New York invested in 97,233 shares. Gemmer Asset Mgmt Ltd Limited Liability Company reported 85 shares. Hotchkis Wiley Mgmt Ltd Liability has invested 0.02% in Meritage Homes Corporation (NYSE:MTH). The South Dakota-based South Dakota Investment Council has invested 0.61% in Meritage Homes Corporation (NYSE:MTH).

Since November 6, 2018, it had 1 buying transaction, and 7 insider sales for $1.85 million activity. $189,400 worth of Meritage Homes Corporation (NYSE:MTH) was sold by HADDOCK GERALD W. Sferruzza Hilla also sold $33,043 worth of Meritage Homes Corporation (NYSE:MTH) on Tuesday, February 12. 10,000 shares valued at $379,040 were bought by BRADFORD DANA on Tuesday, November 6. 19,500 shares were sold by WHITE C TIMOTHY, worth $878,865 on Monday, February 4. $34,680 worth of Meritage Homes Corporation (NYSE:MTH) was sold by Feliciano Javier. On Wednesday, February 13 Lord Phillippe sold $24,165 worth of Meritage Homes Corporation (NYSE:MTH) or 537 shares.

Among 6 analysts covering Meritage Homes (NYSE:MTH), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Meritage Homes had 13 analyst reports since September 21, 2018 according to SRatingsIntel. The rating was downgraded by Wedbush to “Neutral” on Thursday, January 10. JMP Securities maintained the stock with “Market Outperform” rating in Thursday, October 11 report. The stock of Meritage Homes Corporation (NYSE:MTH) earned “Sell” rating by J.P. Morgan on Thursday, March 7. Citigroup maintained Meritage Homes Corporation (NYSE:MTH) on Friday, January 4 with “Buy” rating. The firm has “Neutral” rating given on Friday, September 21 by JP Morgan. Evercore upgraded the stock to “Outperform” rating in Thursday, October 25 report. Citigroup downgraded the shares of MTH in report on Friday, February 1 to “Neutral” rating. Wedbush maintained the stock with “Neutral” rating in Tuesday, March 5 report. The stock has “Neutral” rating by Credit Suisse on Wednesday, October 17. The firm has “Buy” rating given on Monday, October 22 by Deutsche Bank.

More notable recent Meritage Homes Corporation (NYSE:MTH) news were published by: Finance.Yahoo.com which released: “Should You Be Concerned About Meritage Homes Corporation’s (NYSE:MTH) Historical Volatility? – Yahoo Finance” on March 01, 2019, also Streetinsider.com with their article: “Meritage Homes Corporation (MTH) Approves New $100M Buyback – StreetInsider.com” published on February 14, 2019, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For March 7, 2019 – Benzinga” on March 07, 2019. More interesting news about Meritage Homes Corporation (NYSE:MTH) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: Abercrombie, BHP, Coca-Cola, Monster Beverage, Procter & Gamble, Rio Tinto, Toll Brothers and More – 24/7 Wall St.” published on March 07, 2019 as well as Globenewswire.com‘s news article titled: “Meritage Homes Fourth Quarter 2018 Earnings Conference Call and Webcast Scheduled for January 31, 2019 – GlobeNewswire” with publication date: January 04, 2019.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Institutional Positions Chart